Alfact Innovation Will Present Positive Results for Treatment of AIH- and HBV- Related Acute-on-Chronic Liver Diseases at AASLD

Published: Oct 24, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

October 24, 2013 -- Alfact Innovation, a young innovative biotechnology company focused on the discovery and the development of biopharmaceuticals to provide innovative therapies in hepatology and oncology disorders, announced positive results from Phase II clinical trial for treatment of AIH- and HBV- related acute-on-chronic liver diseases.

Alfact Innovation has developed ALF-5755, a recombinant protein of the human protein HIP/PAP with in vivo therapeutic effect on a fas model of Acute Liver Failure.

Acute Liver Failure – ALF – is a rare condition in which the liver rapidly loses its ability to function, resulting in coagulopathy and alteration in the mental status of a previously healthy individual. Despite the improvement in overall survival in the last 20 years due to emergency interventions, ALF remains a life-threatening disease with about 30% of mortality rate. Hence, ALF remains a high unmet medical need.

Thank you for saving the date in your agenda and RSVP to contact.alfact@gmail.com to confirm your interest in attending / receiving more information.

Help employers find you! Check out all the jobs and post your resume.

Back to news